Analysts are confident about the athleisure company's upcoming results, but less sure about its long-term prospects.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Despite a recent third-quarter earnings miss, reporting adjusted EPS of $0.79 versus the expected $0.89 and revenue of $15.31 ...

Lowe’s Cos. or Home Depot—looks like a better buy after earnings? It's close, according to Morgan Stanley, which isn't ...

Morgan Stanley (MS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Morgan Stanley (MS) closed at $128.68 in the latest trading session, marking a +0.22% move from the prior day. The stock lagged the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of ...

Compared to the aggregate P/E ratio of the 21.42 in the Capital Markets industry, Morgan Stanley Inc. has a lower P/E ratio ...

Analysts have set 12-month price targets for Morgan Stanley Direct, revealing an average target of $20.29, a high estimate of ...

Morgan Stanley (MS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

We initiate MS with a Buy rating and $162 PT, as market underestimates durability and scale of earnings rebound underway.